Table 2.

Follow-up measures of medical consumption. Data are weighted for the sampling scheme.

	None of the psychiatric disorder disorders	Anxiety or depressive disorder	Somatoform disorders, undifferentiated *	Somatoform disorder, others *	Total
Medical consumption	(n = 274)	(n = 51)	(n = 94)	(n = 12)	(n = 400)
Data from patient records (1 yr):
Face-to-face contact with FP#:
mean (se) median	4.8 (0.2) 4	7.5 (0.9) 7	6.9 (0.6) 5	9.8 (3.5) 5.5	5.5 (0.3) 4
Somatic prescriptions by FP&:
mean (se) median	8.0 (0.6) 5	13.0 (3.6) 6	12.4 (1.7) 8	14.3 (4.2) 8.5	9.7 (0.7) 5
% use	86%	82%	95%	92%	87%
Antidepressants by FP&:
mean (se) median	0.4 (0.1) 0	3.5 (1.0) 0	2.1 (0.4) 0	4.7 (2.1) 1	1.0 (0.2) 0
% use	7%	40%	32%	58%	16%
Psycholeptics by FP&:
mean (se) median	0.6 (0.1) 0	4.2 (2.5) 0	2.3 (0.6) 0	4.9 (3.2) 0	1.5 (0.4) 0
% use	20%	37%	46%	25%	27%
Data from questionnaire (1/2 yr):
- contact with psychiatrist, psychologist or social worker	14%	59%	39%	68%	23%
- visit to hospital or specialist	48%	43%	48%	33%	48%
- admission to hospital	7%	14%	10%	0%	8%

* Undifferentiated somatoform disorders included chronic pain disorders. Other somatoform disorders: hypochondriasis, somatization disorder and conversion disorder. ^# Consultations and visits within office hours ^&FP prescriptions include repeats by FP of medication that was initiated by specialists